Surgery for limited-stage small-cell lung cancer

Area of Science:

• Oncology
• Thoracic Surgery
• Radiation Oncology
• Medical Oncology

Background:

• Limited-stage small-cell lung cancer (SCLC) is typically treated with chemo-radiotherapy and prophylactic cranial irradiation.
• Despite initial response, relapse rates are high, and cure rates for limited-stage SCLC remain poor.
• Observational studies suggest potential benefit from surgery for stage 1 SCLC, leading to varied clinical recommendations.

Purpose of the Study:

• To evaluate if surgical resection improves overall survival and reduces treatment-related deaths in limited-stage SCLC patients.
• To compare surgical intervention against radiotherapy, chemotherapy, combined chemo-radiotherapy, or best supportive care.

Main Methods:

• Systematic review of randomized controlled trials (RCTs) identified through comprehensive database searches (CENTRAL, MEDLINE, Embase, CINAHL, Web of Science) up to January 2017.
• Inclusion criteria: adults with limited-stage SCLC, medically suitable for resection and radical radiotherapy, randomized to surgery versus other interventions.
• Primary outcomes: overall survival and treatment-related deaths; secondary outcomes: loco-regional progression, quality of life, and adverse events.

Main Results:

• Three RCTs with 330 participants were included, but the evidence quality was judged as very low due to incomplete reporting, unclear risk of bias, and outdated methods.
• Conflicting results on overall survival were reported across studies; one showed better survival with radiotherapy, another showed non-significant improvement with surgery, and a third showed significantly better survival with radiotherapy.
• Postoperative mortality was 7% in one surgical arm versus 0% in the radiotherapy arm; one study indicated less dyspnea with surgery compared to radiotherapy.

Conclusions:

• Current RCT evidence does not support the use of surgical resection for limited-stage SCLC management.
• Conclusions are limited by the low quality and lack of contemporary data in existing trials, potentially affecting generalizability.
• High-quality, prospective RCTs are necessary to definitively assess the benefits of surgical resection versus chemo-radiotherapy for survival and quality of life.